Condition: Cancer · Cancer-related Problem/Condition · Chemotherapy · Sponsor: Pomeranian Medical University Szczecin
Introduction: The number of diagnosed cancers is systematically increasing every year. Cancer patients need to undergo regular blood tests to monitor safety and eligibility for treatment. In case of poor blood results, the chemotherapy session must be omitted. For patients living far from the center, this means unnecessary travel with involvement of helpers, additional costs, increased potential of hospital acquired infections, and frustration associated with missed opportunity for treatment. Aims: The primary aim of this study is to gain knowledge about successful implementation of remote, home monitoring of complete blood count to cancer patients during and after systemic treatment for cancer. The secondary aim of the AMBeR collective study protocol is to pilot new technology, gain more context around future investigations and verify costs and changes in patient treatment pathways. Methodology: The investigators will test implementation of home blood monitoring in three South Baltic Countries (DK, PL, GER). Each site will participate in the implementation study with study group á n=33 (total n=165) and control group n=20 (total n=100). The duration of the study is planned for 4 cycles of chemotherapy for each patient and a 3-month follow up period. The first cycle of learning and training at the Outpatient Daily Clinic, then the remaining 3 cycles of blood monitoring at home. The average cycle length is 21-30 days, number of measurements will be determined individually …
This description comes directly from the study's public registry record.
Bartłomiej Baumert, MD, PhD, DSc · +48 91 4250428 · bartlomiej.baumert@pum.edu.pl
Karolina Szmuc, MSc · +48 91 4250428 · karolina.szmuc@usk1.szczecin.pl
Always discuss trial participation with your own doctor first.
| Department of Oncology, Zealand University Hospital | Næstved, Region Sjælland, Denmark | Recruiting |
| Clinic and Polyclinic for Internal Medicine C, Hematology and Oncology, Palliative Care Unit, University Medical Center | Greifswald, Mecklenburg-Vorpommern, Germany | Recruiting |
| Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine, University Medical Center | Rostock, Mecklenburg-Vorpommern, Germany | Recruiting |
| Department of Oncology and Radiotherapy, University Clinical Center of Gdańsk, | Gdansk, Pomeranian Voivodeship, Poland | Recruiting |
| Department of Hematology and Transplantology | Szczecin, West Pomeranian Voivodeship, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06809101